为您找到相关结果约500个

你是不是要搜索 期刊CAR-T细胞疗法是通过分离患者自身的T细胞，在体外进行重编程并扩增后，再回输到患者进行治疗。目前FDA共批准了两款CAR-T产品，分别是诺华的Kymriah和吉利德的Yescarta。两款产品都是靶向B细胞表面的CD19，但是在CAR的设计有所差异。Kymriah的共刺激域是4-1BB，而... 点击跳转

One Year Kymriah (R) CAR-T-Cell Therapy in Germany

Arrived in Everyday Care Twelve Years of CAR T Cell Therapy with Kymriah((R))

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma

CD19 CAR T Cells

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-Ttreatment in B-ALL

Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T

Beyond CD19 CAR-T cells in lymphoma

Complications after CD19+CAR T-Cell Therapy

Toxicities of CD19 CAR-T cell immunotherapy

CD19-directed CAR T-cell therapy in B-cell NHL

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapseafter CD19 CAR-T therapy

Anti-CD19 CAR T-cells

Will allogeneic CAR T cells for CD19(+) malignancies take autologous CAR T cells 'off the shelf'?

Come across in Everyday Care Two Years of CAR-T-Cell Therapy with Kymriah (R)

CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19(+)HLA-C1(-) Malignant B CellsWhile Sparing CD19(+)HLA-C1(+) Healthy B Cells

为您找到相关结果约500个

共500条页码: 1/34页15条/页